Hypogonadism Treatment Research
Hypogonadism Treatment Research – IAS-167A.
In May of 2015, the FDA issued a cautionary notice regarding the use of existing testosterone replacement products to treat hypogonadism (low testosterone) in men due to the possible increased risk of heart attack and stroke. We are developing an orally delivered proprietary peptide to replace current treatments for hypogonadism that we believe will not cause dangerous side effects.
Our proof of concept experiments so far has demonstrated that:
- The identified lead peptide IAS-167A rescued intra-testicular and serum testosterone formation in testes cultures ex vivo and in vivo in adult male rats rendered hypogonadal by treating them with GnRH antagonist (Cetrorelix) which suppressed LH and testosterone production
Future studies will focus on the optimization of the lead peptide IAS-167A and characterization of its stability in-vivo, evaluation of the efficacy (time-and-dose-effects) of IAS-167A to restore circulating testosterone levels in hypogonadal young LH-suppressed and aging rats (resembling more of the human testicular aging biology), formulation, route of administration, study frequency of treatment and long-term effects, and pharmacokinetics studies.